Tepmetko (tepotinib) is a medication that’s used for adults with metastatic non-small cell lung cancer (NSCLC) with certain mutations in the MET gene. This medication is convenient to take because it’s taken by mouth once a day. But, it commonly causes side effects like swelling, fatigue, and nausea.
Metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) mutations
Tepmetko (tepotinib) is a kinase inhibitor. It targets a kinase called mesenchymal-epithelial transition (MET), which is a protein in your body that signals cells to grow and divide. In some lung cancers, the MET gene, which gives the body instructions on how to make the MET protein, is abnormal (mutated). When the MET protein is made incorrectly, cells grow and divide out of control, leading to tumor growth. By blocking MET, Tepmetko (tepotinib) blocks tumor growth.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Pill that’s taken by mouth
Once-a-day dosing
Targeted therapy that can be used as first-choice for NSCLC with MET mutations
Should be taken with a meal
Commonly causes swelling, fatigue, and nausea
Can cause serious liver injury
Keep Tepmetko (tepotinib) in the original packaging, and don’t transfer the tablets to a pill organizer or other container. Store the medication away from children and pets to keep them safe.
Take your daily dose of Tepmetko (tepotinib) as two 225 mg tablets at one time each day. Take it with food to make sure your body absorbs the medication well.
If you’re having trouble swallowing Tepmetko (tepotinib) tablets, don’t cut, crush, or chew the tablets. Instead, you can place your dose in a glass with 30 mL (2 tablespoons) of tap water. Gently mix until the tablets break up into small pieces (the tablets won’t dissolve completely). Then, drink the mixture right away without chewing any tablet pieces. Add another 30 mL (2 tablespoons) water to the glass, and drink to make sure you’ve taken all the medication for your dose.
Let your healthcare team know if you’re starting any new medications, herbals, or supplements to make sure they’re safe to use with Tepmetko (tepotinib). Tepmetko (tepotinib) can interact with other medications or supplements. These interactions can possibly raise your risk of side effects or make Tepmetko (tepotinib) less effective (not work as well). For example, taking Tepmetko (tepotinib) with the blood thinner dabigatran (Pradaxa) might raise your risk of bleeding.
While you’re taking Tepmetko (tepotinib), make sure to use birth control to avoid becoming pregnant or getting your partner pregnant. Continue to use birth control for 1 week after stopping this medication. Tepmetko (tepotinib) is likely to cause harm to an unborn baby based on studies done in animals.
Tepmetko (tepotinib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: Previous interstitial lung disease | Previous radiation to the lung | Smoking | Previous exposure to certain chemotherapies | Male sex
Lung damage has occurred in some people taking Tepmetko (tepotinib). In rare cases, this lung damage can be life-threatening. In general, you might be at higher risk of lung problems if you’ve had previous lung damage, previous radiation to the lung, you smoke, or you’re male. Other risk factors for lung damage with Tepmetko (tepotinib) can include previous treatment with chemotherapies like paclitaxel (Taxol) and immunotherapies like Keytruda (pembrolizumab). In studies, lung damage occurred within a month to a year of treatment. Tell your healthcare provider right away if you have new or worsened cough, shortness of breath, or fevers. Your provider will probably have you stop taking Tepmetko (tepotinib) while they check up on your lungs.
Tepmetko (tepotinib) might cause liver injury, which can be fatal in rare cases. In studies, some people had serious liver injury within the first month of starting the medication. While you’re taking Tepmetko (tepotinib), alert your healthcare team if you notice pain in the right side of your stomach, yellowing of your eyes or skin, or dark or brown urine.
It’s possible that you won’t feel any symptoms of liver injury, so your provider will order blood tests to check on your liver. You’ll need to get these blood tests done before starting Tepmetko (tepotinib), every 2 weeks for the first few months of treatment, and then monthly after that. If your provider notices signs of liver injury from your blood test results, they might ask you to do blood tests more frequently so they can keep a closer eye on your liver. Depending on how serious the liver injury is, you might need to take a break from Tepmetko (tepotinib) so your liver can recover and then restart the medication at a lower dose or even stop Tepmetko (tepotinib) completely.
In animal studies, Tepmetko (tepotinib) caused birth defects and even death in unborn babies. If you’re able to have children, your provider will ask you to do a pregnancy test before starting Tepmetko (tepotinib). Use birth control if you or your partner is taking Tepmetko (tepotinib), and continue using birth control until 1 week after stopping the medication. Alert your healthcare team right away if you become pregnant while taking Tepmetko (tepotinib).
The typical dose is 450 mg by mouth once a day with food.
Metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) mutations
Metastatic non-small cell lung cancer (NSCLC) with changes in the MET gene
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Cancer Society. (2023). If you have non-small cell lung cancer.
American Cancer Society. (2023). Tests for lung cancer.
American Lung Association. (2021). MET and lung cancer.
EMD Serono, Inc. (2023). Tepmetko- tepotinib hydrochloride tablet [package insert]. DailyMed.
European Medicines Agency. (n.d.). Summary of the risk management plan for Tepmetko (tepotinib).
Le, X., et al. (2022). Tepotinib efficacy and safety in patients with MET exon 14 skipping NSCLC: Outcomes in patient subgroups from the VISION study with relevance for clinical practice. Clinical Cancer Research.
Merck KgaA. (2022). Taking Tepmetko
National Comprehensive Cancer Network. (2023). Metastatic non-small cell lung cancer.
Paik, P. K., et al. (2020). Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. The New England Journal of Medicine.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.